The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2024 | Promising therapeutic efficacy of EBV-specific T-cell immunotherapy tabelecleucel in PTLD
Nina Worel, MD, Medical University of Vienna, Vienna, Austria, discusses the efficacy of allogeneic Epstein-Barr virus (EBV)-specific T-cell immunotherapy, tabelecleucel, in patients with post-transplant lymphoproliferative disease (PTLD). Prof. Worel explains that tabelecleucel utilizes T-cells derived from third-party EBV-immune donors. She emphasizes the development of a tissue-specific T-cell library with various human leukocyte antigen (HLA) systems tailored to individual PTLD cases. Prof. Worel highlights tabelecleucel’s efficacy in treating PTLD with minimal severe adverse events (AEs). This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research grants: Sanofi Genzyme, Therakos Malinckrodt
Advisory Boards: BMS Celgene, Kite Gilead, Novartis, Sanofi Genzyme
Speaker’s fees: Kite Gilead, Novartis, Pierre Fabre, Sanofi Genzyme, Therakos Malinckrodt
Travel Support: BMS Celgene, Kite Gilead, Novartis, Pierre Fabre, Sanofi Genzyme
